Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).

Trial Details

NCT ID
NCT03715933
Phase
PHASE1
Sponsor
Inhibrx Biosciences, Inc
Status
RECRUITING
Cancer Type
Osteosarcoma Sarcoma
Interventions
  • INBRX-109
  • Irinotecan
  • Temozolomide
  • carboplatin
  • pemetrexed
  • Leucovorin
Locations (sample)
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • Beverly Hills, California, United States|34.07362,-118.40036
  • Duarte, California, United States|34.13945,-117.97729
  • Los Angeles, California, United States|34.05223,-118.24368
  • San Diego, California, United States|32.71571,-117.16472

Key Eligibility Criteria

  • Males or females aged ≥12 to less than 85 years for Ewing sarcoma and 18 to less than 85 years of age for other tumors.
  • Part 3 combination therapy expansion tumor types:
  • Histologically confirmed Ewing sarcoma with a classical fusion: Patients with locally advanced or metastatic, unresectable, relapsed, or refractory…
  • Colorectal adenocarcinoma: Patients who have failed 1 (one) prior line of systemic therapy that did not include irinotecan.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →